BridgeMD
New treatment option for Breast Cancer Nos Metastatic Recurrent
Official title Chronic Toxicities Related to Treatment in Patients With Localized Cancer
ClinicalTrials.gov ID: NCT01993498
What this study is testing
- What it's testing
- The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer.
- Time commitment: about 5 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- CANTO - Breast
- Women,
- Aged 18 years and over,
- With an invasive breast cancer diagnosed by cytology or histology,
- No clinical evidence of metastasis at the time of inclusion,
You likely can't join if
- Metastatic breast cancer,
- Local recurrence of breast cancer,
- History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
- Already received treatment for breast cancer ongoing,
- Blood transfusion performed for less than six months,
- Persons deprived of liberty or under supervision (including guardianship). CANTO - Lung Inclusion Criteria:
See the full eligibility criteria
- CANTO - Breast
- Women,
- Aged 18 years and over,
- With an invasive breast cancer diagnosed by cytology or histology,
- No clinical evidence of metastasis at the time of inclusion,
- Untreated including scored for breast cancer surgery in progress,
- Patient receiving a social security system,
- Patient mastering the French language,
- Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
- (Since february 2022) Patient :
- Age \< 45 years at diagnostic
- Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-
- Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib
- Metastatic breast cancer,
- Local recurrence of breast cancer,
- History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
- Already received treatment for breast cancer ongoing,
- Blood transfusion performed for less than six months,
- Persons deprived of liberty or under supervision (including guardianship). CANTO - Lung Inclusion Criteria:
- Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,
- Tumor cTX to cT4, cN0-3,
- No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),
- Eligible for curative treatment by surgery or radiotherapy \ (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)
- Lack of treatment received for current lung cancer, including surgical treatment
- Patient benefiting from a social protection scheme,
- Patient mastering the French language,
- Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption. Exclusion Criteria:
- Metastatic lung cancer,
- Local relapse of lung cancer,
- History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,
- Treatment already received for current lung cancer,
- Blood transfusion carried out less than 6 months ago,
- Persons deprived of liberty or under guardianship (including curatorship).
The study team makes the final eligibility decision.
Where it's taking place
- Villejuif, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Villejuif, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.